PRDM11

Across TCGA pan-cancer cohorts, PRDM11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRDM11 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRDM11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRDM11 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where PRDM11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.868	0.472	.014	13	view →
LUAD	DFS	Median	II,III,IV	0.755	0.969	.007	7	view →
HNSC	OS	Median	All	0.730	0.929	.028	3	view →
GBM	OS	Median	All	0.870	0.537	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRDM11–LSCC (DFS)

Open the LSCC breakdown →